Zaprinast | CAS#37762-06-4 | P. falciparum inhibitor

MedKoo Cat#: 563423 | Name: Zaprinast

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Zaprinast is a phosphodiesterase (PDE) inhibitor that selectively targets PDE5 and PDE6. It was an early lead compound for developing PDE5 inhibitors like sildenafil. Zaprinast increases intracellular cyclic GMP levels, leading to smooth muscle relaxation. It has been studied for its potential effects on cardiovascular function and neuroprotection.

Chemical Structure

Zaprinast

CAS#37762-06-4

Theoretical Analysis

MedKoo Cat#: 563423

Name: Zaprinast

CAS#: 37762-06-4

Chemical Formula: C13H13N5O2

Exact Mass: 271.1069

Molecular Weight: 271.28

Elemental Analysis: C, 57.56; H, 4.83; N, 25.82; O, 11.80

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 200.00
50mg	USD 390.00
100mg	USD 620.00

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Zaprinast;

IUPAC/Chemical Name

5-(2-Propoxyphenyl)-1H-[1,2,3]triazolo[4,5-d]pyrimidin-7(4H)-one

InChi Key

REZGGXNDEMKIQB-UHFFFAOYSA-N

InChi Code

InChI=1S/C13H13N5O2/c1-2-7-20-9-6-4-3-5-8(9)11-14-12-10(13(19)15-11)16-18-17-12/h3-6H,2,7H2,1H3,(H2,14,15,16,17,18,19)

SMILES Code

O=C1C(NN=N2)=C2NC(C3=CC=CC=C3OCCC)=N1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 271.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Kang X, Xie Z, Yang Y, Wu L, Xu H, Zhang S, Liang Y, Wu X. Hippocampal GPR35 is involved in the depression-like behaviors induced by inflammation and mediates the antidepressant effects of fluoxetine in mice. Brain Behav Immun. 2025 Feb 18;126:189-213. doi: 10.1016/j.bbi.2025.02.010. Epub ahead of print. PMID: 39978696. 2: Hu C, Cui T, Xu Z, Yang K, Wu Y, Cai W, Yu J, Qiu Y. Inhibiting HMGB1/AGER/NF-κB pathway prevents pro-inflammatory microglia polarization and protect photoreceptors in retinitis pigmentosa. Int Immunopharmacol. 2025 Mar 6;149:114192. doi: 10.1016/j.intimp.2025.114192. Epub 2025 Feb 3. PMID: 39904032. 3: Gupta RA, Higham JP, Pearce A, Urriola-Muñoz P, Barker KH, Paine L, Ghooraroo J, Raine T, Hockley JRF, Rahman T, St John Smith E, Brown AJH, Ladds G, Suzuki R, Bulmer DC. GPR35 agonists inhibit TRPA1-mediated colonic nociception through suppression of substance P release. Pain. 2025 Mar 1;166(3):596-613. doi: 10.1097/j.pain.0000000000003399. Epub 2024 Oct 3. PMID: 39382322; PMCID: PMC11808708. 4: Oka M, Akaki S, Ohno O, Terasaki M, Hamaoka-Tamura Y, Saito M, Kato S, Inoue A, Aoki J, Matsuno K, Furuta K, Tanaka S. Suppression of Mast Cell Activation by GPR35: GPR35 Is a Primary Target of Disodium Cromoglycate. J Pharmacol Exp Ther. 2024 Mar 15;389(1):76-86. doi: 10.1124/jpet.123.002024. PMID: 38290974. 5: Soares-Santos RR, Machado DP, Romero TL, Duarte IDG. Nitric oxide and potassium channels but not opioid and cannabinoid receptors mediate tramadol- induced peripheral antinociception in rat model of paw pressure withdrawal. Can J Physiol Pharmacol. 2024 Mar 1;102(3):218-227. doi: 10.1139/cjpp-2023-0314. Epub 2023 Nov 17. PMID: 37976474. 6: Herzig S, Li L, Jiménez-Sánchez C, Martinou JC, Maechler P. Screening for new inhibitors of the human Mitochondrial Pyruvate Carrier and their effects on hepatic glucose production and diabetes. Biochim Biophys Acta Gen Subj. 2023 Dec;1867(12):130492. doi: 10.1016/j.bbagen.2023.130492. Epub 2023 Oct 21. PMID: 37871770. 7: Im DS. Recent advances in GPR35 pharmacology; 5-HIAA serotonin metabolite becomes a ligand. Arch Pharm Res. 2023 Jun;46(6):550-563. doi: 10.1007/s12272-023-01449-y. Epub 2023 May 25. PMID: 37227682. 8: Vo KC, Ruga L, Psathaki OE, Franzkoch R, Distler U, Tenzer S, Hensel M, Hegemann P, Gupta N. Plasticity and therapeutic potential of cAMP and cGMP- specific phosphodiesterases in Toxoplasma gondii. Comput Struct Biotechnol J. 2022 Sep 24;20:5775-5789. doi: 10.1016/j.csbj.2022.09.022. PMID: 36382189; PMCID: PMC9619220. 9: Teixeira LRM, Castro Perez A, Lima Romero TR, Gama Duarte ID. Magnesium sulphate activates the L-arginine/NO/cGMP pathway to induce peripheral antinociception in mice. Magnes Res. 2022 Jan 1;35(1):1-10. English. doi: 10.1684/mrh.2022.0495. PMID: 36214549. 10: Xu W, Dong Y, Li Y, Hu Z, Paquet-Durand F, Jiao K. Organotypic Retinal Explant Cultures from Macaque Monkey. J Vis Exp. 2022 Aug 24;(186). doi: 10.3791/64178. PMID: 36094256. 11: Huynh MH, Carruthers VB. Toxoplasma gondii excretion of glycolytic products is associated with acidification of the parasitophorous vacuole during parasite egress. PLoS Pathog. 2022 May 5;18(5):e1010139. doi: 10.1371/journal.ppat.1010139. PMID: 35512005; PMCID: PMC9113570. 12: Thaçi S, Krasniqi B, Dërmaku-Sopjani M, Rifati-Nixha A, Abazi S, Sopjani M. Vasorelaxant Effects of the Vitex Agnus-Castus Extract. Evid Based Complement Alternat Med. 2022 Mar 22;2022:7708781. doi: 10.1155/2022/7708781. PMID: 35360656; PMCID: PMC8964153. 13: Ferreira RCM, de Almeida DL, Duarte IDG, Aguiar DC, Moreira FA, Romero TRL. The antipsychotic aripiprazole induces peripheral antinociceptive effects through PI3Kγ/NO/cGMP/KATP pathway activation. Eur J Pain. 2022 Apr;26(4):825-834. doi: 10.1002/ejp.1910. Epub 2022 Feb 1. PMID: 35044019. 14: Hodges WT, Jarasvaraparn C, Ferguson D, Griffett K, Gill LE, Chen Y, Ilagan MXG, Hegazy L, Elgendy B, Cho K, Patti GJ, McCommis KS, Finck BN. Mitochondrial pyruvate carrier inhibitors improve metabolic parameters in diet-induced obese mice. J Biol Chem. 2022 Feb;298(2):101554. doi: 10.1016/j.jbc.2021.101554. Epub 2021 Dec 30. PMID: 34973337; PMCID: PMC8808181. 15: Megat S, Hugel S, Journée SH, Bohren Y, Lacaud A, Lelièvre V, Doridot S, Villa P, Bourguignon JJ, Salvat E, Schlichter R, Freund-Mercier MJ, Yalcin I, Barrot M. Antiallodynic action of phosphodiesterase inhibitors in a mouse model of peripheral nerve injury. Neuropharmacology. 2022 Mar 1;205:108909. doi: 10.1016/j.neuropharm.2021.108909. Epub 2021 Dec 4. PMID: 34875284. 16: Sanz FJ, Solana-Manrique C, Torres J, Masiá E, Vicent MJ, Paricio N. A High- Throughput Chemical Screen in DJ-1β Mutant Flies Identifies Zaprinast as a Potential Parkinson's Disease Treatment. Neurotherapeutics. 2021 Oct;18(4):2565-2578. doi: 10.1007/s13311-021-01134-2. Epub 2021 Oct 25. PMID: 34697772; PMCID: PMC8804136. 17: Huang L, Kutluer M, Adani E, Comitato A, Marigo V. New In Vitro Cellular Model for Molecular Studies of Retinitis Pigmentosa. Int J Mol Sci. 2021 Jun 16;22(12):6440. doi: 10.3390/ijms22126440. PMID: 34208617; PMCID: PMC8235468. 18: Kurosawa T, Tega Y, Sako D, Mochizuki T, Yamaguchi T, Kawabata K, Inoue K, Ito N, Kusuhara H, Deguchi Y. Transport Characteristics of 6-Mercaptopurine in Brain Microvascular Endothelial Cells Derived From Human Induced Pluripotent Stem Cells. J Pharm Sci. 2021 Oct;110(10):3484-3490. doi: 10.1016/j.xphs.2021.06.007. Epub 2021 Jun 5. PMID: 34102205. 19: Leinonen H, Cheng C, Pitkänen M, Sander CL, Zhang J, Saeid S, Turunen T, Shmara A, Weiss L, Ta L, Ton T, Koskelainen A, Vargas JD, Kimonis V, Palczewski K. A p97/Valosin-Containing Protein Inhibitor Drug CB-5083 Has a Potent but Reversible Off-Target Effect on Phosphodiesterase-6. J Pharmacol Exp Ther. 2021 Jul;378(1):31-41. doi: 10.1124/jpet.120.000486. Epub 2021 Apr 30. PMID: 33931547; PMCID: PMC8456514. 20: Zhang Y, Shi T, He Y. GPR35 regulates osteogenesis via the Wnt/GSK3β/β-catenin signaling pathway. Biochem Biophys Res Commun. 2021 Jun 4;556:171-178. doi: 10.1016/j.bbrc.2021.03.084. Epub 2021 Apr 8. PMID: 33839412.